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Acute intermittent porphyria (AIP) is a neuropathic disease caused by a dominant inherited deficiency in porphobilinogen deaminase (PBGD).We
investigated the expression and the degradation of the human PBGD-mutations G748A, G748C and 887insA following transfection into human SH-
SY5Y neuroblastoma cells. Mutant proteins exhibited reduced protein expression compared to transfected wild-type (wt) PBGD as revealed by
Western blotting. The transcription levels assessed by real-time PCR of these mutant species were identical to those of the wild type. Immuno-
fluorescence microscopy revealed reduced cellular distribution of the mutated PBGDs in the cytosol and the nucleus in comparison to the wild-type
PBGD. Enhanced cellular accumulation of the mutated and wild-type PBGDs was detected following inhibition of the proteasome by the inhibitors
CLBL and hemin. Elevated expression of wt and mutated PBGD protein levels was either achieved by hemin or heme-arginate treatment. On the
other hand, enhanced PBGD degradation was achieved by lead poisoning of ALAD in the SH-SY5Y cells concomitant with acceleration of
proteasomal activity, most probably by ALAD participation in proteasomal regulation [G.G. Guo, M. Gu, J.D. Etlinger, 240-kDa proteasome
inhibitor (CF-2) is identical to delta-aminolevulinic acid dehydratase. J Biol Chem 1994; 269:12399–402.] Our results suggest that the difference
in expression between the wild-type and mutant proteins appears to be regulated on the level of protein degradation. In conclusion, we
demonstrate that the PBGD cellular pool is controlled by the proteasome activity, which in turn is down regulated by hemin or up-regulated by
Pb-ALAD.
© 2006 Elsevier B.V. All rights reserved.Keywords: AIP; PBGD; Proteasome; Hemin; ALAD1. Introduction
Porphyrias are a family of human inherited diseases, each
associated with a partial defect in one of the heme biosynthetic
enzymes. Each porphyrinopathy therefore is associated with
specific metabolic abnormalities, reflected by diagnostic
laboratory findings in the blood, urine and stool of the affected
individual [1]. Acute intermittent porphyria (AIP) is a severe
form of porphyria, and is caused by a dominant, inherited partial
deficiency of the heme biosynthetic enzyme, porphobilinogen
deaminase (PBGD) [2,3].
The frequency of AIP is around 1–10:100,000 globally, and
only in a few villages in northern Sweden the frequency reaches
2:100 or 5:1000 because of a founder effect. [4,5]. AIP is⁎ Corresponding author. Tel.: +972 3 5318204; fax: +972 3 5345878.
E-mail address: malikz@mail.biu.ac.il (Z. Malik).
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doi:10.1016/j.bbadis.2006.07.005clinically associated with life-threatening neuropathy attacks,
including autonomic neuropathy with abdominal pain, vomit-
ing, constipation, hypertension, tachycardia and bladder dys-
function [6–8]. Hemin and heme-arginate are used clinically for
the management of AIP, mainly to reduce the acute symptoms
[5,9]. Lead poisoning is clinically manifested by an AIP-like
disorder and has been successfully treated with hemin [10].
Recently we have demonstrated that lead poisoning of neuro-
blastoma cells induces proteasomal degradation of PBGDwhich
correlates with the inhibition of ALA-dehydratase [11].
The regulation of the heme synthesis pathway is under the
control of the first enzyme, ALA-synthetase, and the last
enzyme, ferrochelatase [1–3,5,7,8]. It has been reported that
hemin is a specific inhibitor of the catalytic activity of the pro-
teasome [12,13], while ALAD (ALA-dehydratase) acts as the
CF-2 regulatory subunit of the proteasome [14]. In the presence
of hemin, polyubiquitinated cystic fibrosis transmembrane
conductance regulator (CFTR) remains undegraded by the
820 N. Grünberg-Etkovitz et al. / Biochimica et Biophysica Acta 1762 (2006) 819–827proteasome in cell-free and microsomal CFTR systems, indicat-
ing that hemin inhibits the catalytic activity of the core
proteasome enzymes [15].
The PBGD enzyme is known to be the synthesis rate-limiting
determinant of the heme molecule. Its gene encodes two
isoenzymes formed by an alternative splicing process. The first
is a housekeeping form that is available in all tissues, whereas
the second is specific only for erythroid cells [16]. To date,
according to “Gene Mutation Database”, 246 mutations have
been described within the PBGD gene, including deletion/
insertion and point mutations [17–21]. An experimental model
based on PBGD-deficient mice (PBGD−/−) showed that these
mice develop impairment of motor coordination, and muscle
weakness [22]. The prevailing theories are that the neuropathy
in AIP may be due to a lack of heme in the nervous tissue, to an
excess of the heme pathway intermediates, ALA and PBG, or
may be induced indirectly by the metabolic consequences of
heme deficiency in the liver [23,24].
We have shown that PBGD is imported into the nucleus of
various cell lines and of primary cells, and has a nuclear
function separate from the cytoplasmic pool, where PBGD
participates in heme synthesis [25]. Moreover, using a two-
hybrid screen, we revealed an interaction between PBGD and
the nuclear Ran-binding factor, RanBPM, whose function is as
yet unknown [26]. Much is known about the biochemical
consequences of PBGD defects; however, the origin of the
neurological manifestations remains unresolved.
The aims of the present study were to examine the
transcription, expression and sub-cellular localization of three
common AIP mutations, G748A, G748C and 887insA,
which were constitutively expressed in a human neuroblas-
toma cell line. We examined the inhibitory effect of hemin/
heme-arginate and Clasto-lactacystin B-lactone (CLBL) on
proteasomal degradation of PBGD and the consequences of
hemin-mediated inhibition on the expression of mutant
PBGD forms. Alternatively, we accelerated the proteasome
activity by lead poisoning of the second enzyme of the heme
biosynthetic pathway, 5-aminolevulinic acid-dehydratase
(ALAD). We demonstrate that the PBGD cellular pool is
an example of a regulatory mechanism controlled by hemin
via the proteasome.
2. Materials and methods
2.1. Cell culture
Human SH-SY5Y neuroblastoma cells were grown in tissue culture plates
(Corning, Staffordshire, UK) in DMEMmedium (Biological Industries, Kibbutz
Beit-Haemek, Israel), supplemented with 10% fetal calf serum and antibiotics,
and incubated at 37 °C in a humidified atmosphere with 8% CO2. Cells were
treated with 10 μM Clasto lactacystin β-lactone (Sigma), 100 μM hemin
(Sigma) or 100 μM heme-arginate (Orphan Europe).
2.2. Construction of mutated-PBGD constructs
The coding region of the human PBGD was amplified from the PBGD-
expression vector as described [25], with the forward primer: 5′-CGGGAT-
CCCGGCCGCCACCATGGCTTACCCATACGATGTTCCAGATTACGC-
TATGTCTGGTAACGGCAATGCGGC-3′ containing the HA-tag, and reverseprimer: 5′-CGGGATCCCGTTAATGGGCATCGTTAAGCTGCCG-3′. The
1138 bp PCR product was inserted into the pLY-3 vector, as described [25],
yielding a new plasmid named pHA-PBGD plasmid, which expresses the wild-
type PBGD in mammalian cells. The PBGD mutants were amplified (forward:
5′-GCTTCGCTGCATCGCTCAAAGGGCCTTCCTGAG-3′ and reverse: 5′-
CTCAGGAAGGCCCTTTGAGCGATGCAGCGAAGC-3′ for the G748C
mutant, forward: 5′-GCTTCGCTGCATCGCTAAAAGGGCCTTCCTGAG-3′
and reverse 5′-CTCAGGAAGGCCCTTTTAGCGATGCAGCGAAGC-3′ for the
G748A mutant, forward: 5′-CAAGAGACCATGCAAGGCTACCATCCATGTCC-
3′ and reverse: 5′-GGACATGGATGGTAGCCTTGCATGGTCTCTTG-3′ for
the 887insA mutant) using the circle pHA-PBGD plasmid, by the high fidelity
PfuTurbo® DNA polymerase (Stratagene, La Jolla, CA). Immediately after the
PCR reaction, 10 units of DpnI enzyme were added to each reaction for 1 h at
37 °C, for digestion of methylated DNA sequences. The DNA products were
transformed into competent bacterial cells using the heat-shock method. The
cells were plated on LB medium containing Kanamycin. Constructs were
verified by sequencing (Weizmann Institute Biological Services, Rehovot,
Israel).
2.3. Stable cell transfection
The plasmids were transfected into SH-SY5Y cells, using lipofectamine
reagent (GIBCO-BRL, Gaithersburg, MD) according to the manufacturer's
protocol. For stable transfection, selective medium containing 1100 μg/ml
G418 (GIBCO-BRL, Gaithersburg, MD) was added to the cells 24 h post-
transfection. The surviving G418-resistant colonies on each plate were then
sub-cloned by dilution and grown to establish the sub-lines. For selection
maintenance, the cells were selectively grown in a medium containing
200 μg/ml G418.
2.4. RT-PCR of PBGD-mutants
Total RNA was extracted from PBGD-mutant expressing SH-SY5Y cells
using an RNeasy Mini Kit (Qiagen GmbH, Hilden, Germany). RT-PCR was
carried out using RT-PCR beads (Amersham Pharmacia, Piscataway, NJ)
according to manufacturer's instructions, using 5′-ATGGCTTACCCATAC-
GATGTT-3′ forward primer and 5′-TTAATGGGCATCGTTAAGCTG-3′
reverse primer.
2.5. Real-time quantitative RT-PCR of PBGD mutants
An amount of 3 μg total RNA extracted from mutant-PBGD expressing
SH-SY5Y cells was reverse transcribed with Expand reverse transcriptase
(Roche), using the reverse primers for PBGD and β-actin (20 pmol of each).
The forward primer for PBGD was homologous to the HA-tag: 5′-CTT ACC
CAT ACG ATG TTC CAG AT-3′, and the reverse primer was: 5′-GTA CCC
ACG CGA ATC ACT CT-3′. For the reference gene, β-actin, we used the
forward primer 5′-TCA CCC ACA CTG TGC CCA TCT AC-3′ and reverse
primer: 5′-CAG CGG AAC CGC TCA TTG CCA AT-3′. Real-time
quantitative PCR was carried out with DyNAmo HS SYBR Green qPCR
kit (Finnzymes, Finland). The amplifications were performed in a thermo-
cycler (DNA Engine Opticon 2, MJ Research) with the following thermal
profile: 95 °C for 15 min followed by 40 cycles of 94 °C for 10 s, 59 °C for
25 s, 72 °C for 30 s, plate read, 78 °C for 1 s, melting curve program from
65 °C to 95 °C, with a heating rate of 0.5 °C/s, cooling program down to
30 °C. Each sample was replicated three to five times. Standard curves
constructed with serial dilutions of cDNA were generated for each transcript
in triplicates. Each assay included a non-RT control and a non-template
control.
Data acquisition was performed using the Opticon Monitor 2 software. The
relative expression ratio of the genes of interest was computed by use of the
following equation [27]:
Ratio ¼ ðEtargetÞDCPtargetðcontrolsampleÞ=ðEreferenceÞΔCPreferenceðcontrolsampleÞ:
RT-PCR data were tested for statistical significance by a pair-wise fixed
reallocation randomization test as implemented by REST [28].
Fig. 1. Constitutive over-expression of mutated-PBGDs in SH-SY5Y human
neuroblastoma cells. (A) Protein expression analysis of the lysates from cells
over-expressing wt and mutated HA-PBGDs. The PBGD proteins were
identified using the anti-HA-tag antibodies, whereas the actin protein was
identified as an internal control. (B) Densitometric analysis of the blots in panel
A. The values are the ratio between HA-PBGD/actin optical densities.
Fig. 2. mRNA expression of mutated HA-PBGDs (A) Quantification of mRNA
levels of the mutated PBGDs in the cells, using RT-PCR. Specific identification
of the exogenous proteins was achieved by using primers homologous to the HA
sequence at the 5′ prime and to the end of the PBGD sequence. 18S rRNAwas
used as an internal control. (B) Quantitative RT-PCR of the mutated PBGDs in
the cells. Specific identification of the exogenous proteins was achieved by
using primers homologous to the HA sequence at the 5′ prime and to a sequence
within the PBGD gene. β-actin mRNA was used as an internal control.
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Cells were detached from plates and centrifuged, pellets were resuspended and
homogenized in 250 μl 50 mM Tris (pH 8.2), containing 0.2% Triton X-100. In
brief, PBGD was assayed by determining the absorbance of uroporphyrin formed
by light-induced oxidation of uroporphyrinogen, which is the immediate product of
the enzymatic deamination. PBGD specific activity was calculated as described
[25], as pmol uroporphyrin formed/mg protein/h (ex. 409 nm, em. 595 nm).
2.7. Western blotting
Proteins were quantified using the Bradford assay (Bio-Rad, Hercules, CA)
and resolved on a 12% polyacrylamide gel. The proteins were then transferred
onto nitrocellulose membranes using a semi-dry transfer apparatus (Bio-Rad,
Hercules, CA). After blocking, the membranes were incubated with primary
monoclonal antibodies against the HA-tag (Berkeley Antibody Company,
Richmond, CA) or actin (Sigma) or rabbit anti-PBGD antibodies (a generous gift
from HemeBiotech, Sweden) and HRP anti-mouse/rabbit secondary antibody
(Jackson Immuno-Research, West Grove, PA). Immuno-reactive proteins were
visualized with either SuperSignal® West Pico (Amersham Pharmacia, Piscat-
away, NJ) or LumiGLO® (KPL, Gaithersburg,MD), according tomanufacturer's
instructions. Densitometric analysis was performed with “Image J” software.2.8. PBGD immunolabeling
SH-SY5Y cells expressing PBGD mutants were fixed using 4% para-
formaldehyde, subsequently washed and incubated for 1 h with blocking
solution containing 0.5% Triton X-100, 1% BSA, and 10% FCS in PBS,
following incubation with anti-HA-tag antibody overnight at 4 °C and
thereafter with goat anti-mouse secondary antibody (Alexa Fluor® 568,
Molecular Probes). The cells were visualized by fluorescence microscopy
(Vanox AHBT3 microscope). As a control, cells were incubated with only the
secondary antibody.
2.9. Proteasome activity assay
Cells were detached from plates and centrifuged, pellets were resuspended and
homogenized in 250 μl 100 mM Tris (pH 7.5), containing 1% Triton X-100.
Lysates were incubated with 13 μM of the fluorogenic proteasome substrate
N-Succinyl–Leu–Leu–Val–Tyr-7–Amido-4–Methylcoumarin (Sigma) in the
same buffer but without detergent for 1 h at 37 °C with shaking. Ice-cold ethanol
(100%) was added, and the samples were analyzed by a HPLC system LaChrom
D-7000 (Merck Hitachi) utilizing a FL detector L-7480. Data acquisition was
performed by the HSM software and further analyzed by Microsoft Excel.
2.10. ALAD enzymatic activity assay
Cells were washed and detached from plates using 0.1 M Tris (pH 7.2)
containing 0.25 M sucrose. After centrifugation, pellets were resuspended in
Fig. 3. PBGD enzymatic activity of the cells expressing PBGD mutants. Data
represent mean of three independent experiments±SD (each performed in
triplicate), *p<0.01.
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incubated in a final concentration of 5 mM ALA (Fluka, Switzerland), 1 mM
DTT (Sigma), 0.1 mM Zn2+ (Sigma) in 150 μl of 0.1 M Tris–acetate buffer (pH
7.2), for 2 h at 37 °C with shaking. The reaction was stopped by addition of 6%
TCA and formed PBG was developed by the Ehrlich's reagent [29] and
measured spectrophotometrically (em. 555 nm) (Spectronic Instruments, Leeds,
UK). ALAD specific activity was calculated as pmol PBG formed/mg protein/
2 h units [30].Fig. 4. Sub-cellular localization of mutated-PBGDs in SH-SY5Y cells. The PBGD m
using antibodies against HA-tag and Alexa Fluor® 568 secondary antibody. The cel3. Results
3.1. Expression of mutated-PBGD constructs in neuroblastoma
cells
We constructed three PBGD-expression vectors tagged to
hemagglutinin, encoding the PBGD mutants G748A, G748C
and 887insA, which are responsible for severe phenotypes of
human AIP [31–33]. The mutant vectors, as well as the wild-
type PBGD, were constitutively over-expressed within human
neuroblastoma SH-SY5Y cells; we chose this cell line to reflect
the neuropathology of AIP. Protein expression was analyzed by
Western blotting, using anti-HA antibodies. The results show
high levels of wild-type PBGD protein (44 kDa), while the
mutant proteins G748A and G748C (glutamine mutated to
lysine or alanine) displayed a weak band of 44 kDa proteins
detected by HA-tag antibodies (Fig. 1A and B). The truncated
PBGD mutant, 887insA (frame-shift mutation), was found to
express a very weak 35 kDa band.
3.2. mRNA expression of wt and mutated HA-PBGDs
The reduced protein expression of the mutated PBGD
forms could be attributed to reduced mRNA expression or toutants and the wild-type protein were identified within the transfected cells by
ls were visualized with fluorescence microscopy.
Fig. 5. Hemin-induced proteasomal-activity inhibition and its effect on wt-
PBGD expression in SH-SY5Y cells. (A) Proteasome enzymatic activity in
hemin-treated SH-SY5Y lysates. Data represent mean of three independent
experiments±SD (each performed in duplicate), *p<0.01. Data are presented as
arbitrary units (a.u.). (B) Time-dependent expression of wild-type PBGD in cells
treated with hemin (100 μM) for 4–24 h. The nitrocellulose blot was reacted
against the anti-HA-tag antibodies, whereas the actin protein was used as an
internal control. (C) Densitometric analysis of the blots in panel B.
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using a forward primer containing the HA sequence at the 5′
end, and a reverse primer that is homologous to the end of the
PBGD sequence, showed that the cells expressing the mutant
and the wild-type contain identical levels of PBGD transcripts
(Fig. 2A). In order to validate that mRNA levels of the
mutants compared to the wild-type are not changed at the
transcriptional level, we carried out real-time PCR. The real-
time PCR assay using a forward primer containing the HA
sequence at the 5′ end, and a reverse primer that is homo-
logous to a sequence within the gene, showed negligible up-
regulation of two of the three mutants analyzed, as calculated
by REST [28] (Fig. 2B). The virtually identical mRNA
levels of these PBGD vectors indicate that the reduced
protein quantities of the mutants are not due to reduced
transcription.
3.3. PBGD enzymatic activity of the cells expressing PBGD
mutants
PBGD activity in SH-SY5Y cells expressing the mutants
was moderately reduced in the G748C, G748A and 887insA
mutants, respectively, compared to the non-transfected cells
(Fig. 3). In the wild-type PBGD over-expressing cells, the
enzymatic activity increased only moderately compared to the
non-transfected cells. The reduction in the enzymatic activity
points to a dominant negative effect of the mutants.
3.4. Mutant PBGDs are distributed in the nuclear and cytosolic
compartments
PBGD acts as the third enzyme of the heme synthesis
pathway [34]. We have previously demonstrated the localiza-
tion of wt-PBGD in the cytosol and the nucleus of different cells
[25,26]. Fluorescence microscopy (Fig. 4) demonstrated similar
distribution of the three mutants (Fig. 4C–E) and of the wild-
type PBGD (Fig. 4B) in the cell compartments. Image
acquisition was performed under optimal and identical
illumination conditions to prevent over-excitation and emis-
sion-saturation of fluorescence, while giving a semi-quantita-
tive comparison of the different images. The fluorescence
intensity of the images of Fig. 4 clearly depicts reduced
abundance of the mutant PBGD forms as compared to the wt-
PBGD in the cytosol and nucleus.
3.5. The effect of proteasomal activity inhibition on HA-PBGD
expression
The low levels of mutant protein expression in addition to
constant mutant mRNA transcription, led us to suspect that a
degradation mechanism might be involved in the reduced
levels of mutant proteins. Thus, in order to determine whether
mutant-PBGDs levels increase under proteasome inhibition
we used two known proteasome inhibitors, CLBL and the
therapeutic agents hemin and heme-arginate applied in AIP
therapy [5,9]. Fig. 5A demonstrates the hemin-induced
inhibition of the proteolytic activity in SH-SY5Y cells, andthe increase in wild-type-PBGD protein levels in a time-
dependent manner of hemin-treatment is shown in Fig. 5B
and C, as detected by anti-HA-tag antibody. Furthermore,
CLBL-treatment of cells expressing the wild-type-PBGD
resulted in an accumulation of HA-PBGD (Fig. 6A and B),
similarly to the effect of hemin in the same experiment. The
protein levels of the mutated PBGDs, G748A/C and 887insA,
were markedly increased by either CLBL, hemin or heme-
arginate treatment (Fig. 6C–H), indicating a noticeable
accumulation of the mutated PBGDs in the cells as a result
of proteasome inhibition by either of the three proteasomal
inhibitors.
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and its effect on endogenous wt-PBGD
Lead poisoning is a well-known cause of AIP-like symp-
toms in human due to inhibition of ALAD [34], which is
reverted by the cofactor Zn2+ [35]. Recently, we have
demonstrated that SH-SY5Y cells exposed to lead acetate
for 72 h reveal an inhibition of ALAD enzymatic activity to
less than 40% [11], and an acceleration of proteasomal
activity to more than 200%. Fig. 7A presents the correlationsFig. 6. The effect of the proteasome-activity inhibitors CLBL, hemin, and heme-a
Expression of wild-type PBGD in cells treated with CLBL (10 μM, 4 h) or hemin (10
and the actin protein was used as an internal control. (B) Densitometric analysis of th
(10 μM, 4 h). The nitrocellulose blot was reacted against the same antibodies mentio
mutated PBGDs in cells treated with hemin (100 μM, 24 h) and analyzed as in panel
PBGDs in cells treated with heme-arginate (100 μM, 24 h) and analyzed as in panebetween ALAD, PBGD and proteasomal activities under lead
poisoning conditions. The sharp reduction in ALAD activity
was observed at the low concentration of 1 μM lead acetate
and was accompanied by a marked acceleration of pro-
teasomal activity. The slope of the concomitant reduction in
PBGD activity is moderate, reaching the maximum at a
concentration of 10 μM lead acetate. The reduction of
PBGD activity is due to the degradation of PBGD (Fig. 7B).
This result implies that the reduced expression of PBGD
under Pb2+-poisoning is due to increased PBGD degradationrginate on wt and mutated HA-PBGDs accumulation in SH-SY5Y cells. (A)
0 μM, 24 h). The nitrocellulose blot was reacted against anti-HA-tag antibodies,
e blots in panel A. (C) Expression of mutated PBGDs in cells treated with CLBL
ned above. (D) Densitometric analysis of the blots in panel C. (E) Expression of
C. (F) Densitometric analysis of the blots in panel E. (G) Expression of mutated
l C. (H) Densitometric analysis of the blots in panel G.
Fig. 6 (continued).
Fig. 7. The effect of lead poisoning on ALAD, proteasome and endogenous wt-
PBGD. (A) Enzymatic activity of ALAD (▴), PBGD (●) and proteasome (◼) in
lysates from SH-SY5Y cells treated with 1 μM, 10 μM lead acetate or untreated
cells. (B) The effect of lead acetate on the expression of wt-PBGD. The cells
were treated with 10 μM lead acetate for 72 h followed by Western analysis. The
nitrocellulose blot was reacted against anti-PBGD antibodies, actin protein was
used as an internal control; the graph demonstrates the densitometric analysis of
the blots.
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post lead poisoning.
4. Discussion
To date, PBGD-deficiency and its relation to the patho-
genesis of neurological dysfunction in AIP syndromes remain
elusive. Two prevailing hypotheses have to be considered, the
one that accumulation of ALA (a precursor of heme
synthesis) is toxic to neuronal tissue, and the other that a
decrease in heme and hemeproteins in the nervous system
causes the pathology [36–38]. The second hypothesis, pro-posing heme deficiency as the fundamental origin for altered
physiological activities, has to be assessed.
The present results revealed two main pieces of evidence, the
one, low protein levels of mutant PBGD proteins compared to
the wild-type as analyzed by Western blotting and immunola-
beling; and the second, constant mRNA levels of the mutant
PBGDs (Figs. 1, 2, and 4). In general, when low protein levels
are measured, while constant mRNAs are assessed, one may
assume that low translation rate or high degradation of the
protein is the basis of this phenomenon. Furthermore, it is
conceivable that low levels of mutated PBGD proteins are due
to increased proteasomal degradation of the abnormal proteins.
The over-expression of proteins may vary according to the
transfection technique which may produce a transient transfec-
tion with the vector or after selection will end up with a stably
transfected cell line. It is well documented that variable to high
(15–200%) PBGD enzymatic activity is achieved after transient
transfection with the wt-PBGD vector [39,40]. In general, stably
transfected cells produce lower amounts of the transfected
protein which may also vary with the number of the integrated
plasmid copies, as can be seen in the present results.
The recognition that abnormal proteins are degraded by the
proteasome machinery is well documented and is dependent on
ubiquitination of the target protein [41]. We examined the
possibility that abnormal PBGD forms are degraded via the
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SH-SY5Y cells were therefore treated with the cell permeable,
highly specific 20S proteasome inhibitor CLBL [42,43], or with
the therapeutic agents hemin and heme-arginate used in clinical
therapy of AIP and lead poisoning [5,9,10]. Following
treatment with either hemin, heme-arginate or CLBL, the
over-expressed PBGD mutants accumulated dramatically, as
detected byWestern blotting (Fig. 6C–H). The wild-type PBGD
also accumulated after hemin or CLBL treatment (Fig. 6A and
B). This finding can explain the low levels of mutant expression
compared to the high levels of the wild-type PBGD detected by
Western blotting using the HA-tag antibodies (Fig. 1A and B).
We have recently shown the opposite phenomenon following
lead intoxication; ALA-dehydratase activity was inhibited and
consequently high proteasomal activity was revealed [11]. We
show here that lead acetate induced a reciprocal effect, the
inhibition of ALAD activity accelerating the proteasomal
activity which led to increased PBGD degradation. The possible
underlying mechanism for this phenomenon is the finding that
the ALA-dehydratase enzyme is identical to the proteasomal
inhibitory protein complex CF-2 as reported by Guo et al. [14].
In a recent review ALAD is listed among protein regulators of
the proteasome which control the intensity of its activity in the
cell [44]. Lead poisoning and acute intermittent porphyria (AIP)
exhibit similar neurologic manifestations; despite their simila-
rities, the possible pathophysiologic connection between AIP
and lead poisoning is not known [45]. Intravenous hematin
administration produces biochemical improvement in AIP, and
similarly in lead intoxication hematin administration results in
significant diminution of urinary ALA and coproporphyrin
excretion [10].
In conclusion, this study provides evidence that mutant
PBGDs are degraded through the proteasomal pathway which
in turn can be blocked by hemin and thus up-regulate PBGD
abundance in the cells, whereas Pb2+ poisoning enhances
proteasomal activity and PBGD degradation. We suggest that
successful clinical use of hemin/heme-arginate is related to the
reduced proteasomal degradation of AIP mutant proteins which
triggers cellular increase of PBGD.
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